Corticosteroid therapy for autoimmune pancreatitis
10.3969/j.issn.1001-5256.2018.08.002
- VernacularTitle:自身免疫性胰腺炎的激素治疗
- Author:
Juan MA
1
;
Yulan LIU
Author Information
1. Department of Gastroenterology, People′s Hospital, Peking University, Beijing 100044, China
- Publication Type:Research Article
- Keywords:
pancreatitis;
autoimmune diseases;
glucocorticoids;
therapeutics
- From:
Journal of Clinical Hepatology
2018;34(8):1599-1603
- CountryChina
- Language:Chinese
-
Abstract:
Autoimmune pancreatitis (AIP) is a special type of autoimmune-mediated chronic pancreatitis and has unique imaging, serological, and histopathological features. According to current international guidelines, AIP is classified into type I and type II. Studies have shown that glucocorticoids have a good clinical effect in the treatment AIP, and the guidelines recommend oral glucocorticoids as the preferred treatment regimen for patients without contraindications. However, no consensus has been reached on initial dosage of glucocorticoids and treatment regimens after recurrence. Therefore, with reference to recent research advances and recommendations in guidelines, this article elaborates on the selection of treatment regimens for AIP from the aspects of the selection and treatment of previously untreated AIP patients and the treatment of patients with recurrence.
